Oncology and Hematology

193-208 of 595

• 

  RestartResume

  Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies

  RestartResume

  Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies

  Project Oncology®

  Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies

  • 

    

    Brian Slomovitz, MD

• 

  RestartResume

  Subcutaneous Pembrolizumab in mNSCLC: A Potential Shift in the Delivery Landscape

  RestartResume

  Subcutaneous Pembrolizumab in mNSCLC: A Potential Shift in the Delivery Landscape

  Project Oncology®

  Subcutaneous Pembrolizumab in mNSCLC: A Potential Shift in the Delivery Landscape

• 

  RestartResume

  From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care

  RestartResume

  From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care

  Project Oncology®

  From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care

• 

  RestartResume

  Putting Patients First: Personalized Care in Metastatic Breast Cancer

  RestartResume

  Putting Patients First: Personalized Care in Metastatic Breast Cancer

  On the Frontlines of Metastatic Breast Cancer

  Putting Patients First: Personalized Care in Metastatic Breast Cancer

  • 

    

    Ashley Baker, MSN, PMHNP

  • 

    

    Giancarlo Moscol, M.D.

• 

  RestartResume

  Disaster-Proofing Colorectal Cancer Screening: What We Learned from COVID-19

  RestartResume

  Disaster-Proofing Colorectal Cancer Screening: What We Learned from COVID-19

  Clinician's Roundtable

  Disaster-Proofing Colorectal Cancer Screening: What We Learned from COVID-19

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

  • 

    

    Gloria Coronado, PhD

• 

  RestartResume

  Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access

  RestartResume

  Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access

  Project Oncology®

  Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

  • 

    

    Matthew Lunning, DO, FACP

• 

  MinuteCE®

  Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma

  1.00 credit 10 episodes

  • 

    

    John M. Kirkwood, MD

  • 

    

    Paolo A. Ascierto, MD

  • 

    

    Hussein Tawbi, MD, PhD

  • 

    

    Sapna Patel, MD

  1.00 credit 10 episodes

• 

  MinuteCE®

  Reimagining Lung Cancer Treatment: A Journey Through New and Emerging Therapeutics Related to the Care of Patients with Small Cell and Non-Small Cell Lung Cancer

  1.25 credits 9 episodes

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 credits 9 episodes

• 

  RestartResume

  Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)

  RestartResume

  Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)

  MinuteCE®

  Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• 

  RestartResume

  Novel Therapies in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

  RestartResume

  Novel Therapies in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

  MinuteCE®

  Novel Therapies in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• 

  RestartResume

  Applications of Emerging Data in Resectable NSCLC

  RestartResume

  Applications of Emerging Data in Resectable NSCLC

  MinuteCE®

  Applications of Emerging Data in Resectable NSCLC

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• 

  RestartResume

  The Current Therapeutic Landscape in Unresectable Stage III NSCLC

  RestartResume

  The Current Therapeutic Landscape in Unresectable Stage III NSCLC

  MinuteCE®

  The Current Therapeutic Landscape in Unresectable Stage III NSCLC

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• 

  RestartResume

  Strategies in EGFR-mutated Unresectable Stage III NSCLC

  RestartResume

  Strategies in EGFR-mutated Unresectable Stage III NSCLC

  MinuteCE®

  Strategies in EGFR-mutated Unresectable Stage III NSCLC

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• 

  RestartResume

  Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC

  RestartResume

  Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC

  MinuteCE®

  Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• 

  RestartResume

  HER2-Driven Strategies in Metastatic NSCLC

  RestartResume

  HER2-Driven Strategies in Metastatic NSCLC

  MinuteCE®

  HER2-Driven Strategies in Metastatic NSCLC

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• 

  RestartResume

  MET and Other Emerging Targets in Metastatic NSCLC

  RestartResume

  MET and Other Emerging Targets in Metastatic NSCLC

  MinuteCE®

  MET and Other Emerging Targets in Metastatic NSCLC

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• Previous
• 1
• 2
• …
• 11
• 12
• 13
• 14
• 15
• …
• 37
• 38
• Next